GlassScriptPhysician profile
Christen M Benke
NPI 1649439563
$2,917.68
in general payments reported to CMS, 2019-2025
26 companies · $532 in 2025
The $532 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $474 · 2021: $593 · 2022: $41.79 · 2023: $379 · 2024: $447 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $364.84 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $330.03 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $305.69 | 2019-2023 | |
| Abbvie INC. | $232.92 | 2020-2024 | Qulipta |
| Novo Nordisk INC | $222.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $158.77 | 2019-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $146.55 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $146.21 | 2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $118.18 | 2019-2025 | Breztri |
| Biohaven Pharmaceuticals, INC. | $114.80 | 2020-2021 | |
| Gilead Sciences, INC. | $111.32 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $109.80 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Amarin Pharma, INC. | $94.27 | 2019-2021 | |
| Exact Sciences Corporation | $88.91 | 2023-2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $67.76 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $60.41 | 2019 | |
| Phadia US INC. | $38.24 | 2021 | |
| Sanofi-Aventis U.S. LLC | $37.49 | 2019-2024 | |
| Viiv Healthcare Company | $37.30 | 2025 | Apretude |
| Janssen Pharmaceuticals, INC | $34.48 | 2019 | |
| Astellas Pharma US INC | $19.15 | 2024 | Veozah |
| Antares Pharma, INC. | $18.02 | 2021 | |
| Shire North American Group INC | $16.89 | 2019 | |
| Genentech USA, INC. | $14.58 | 2019 | |
| Avion Pharmaceuticals | $14.48 | 2020 | |
| Therapeuticsmd, INC. | $14.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christen Benke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.